*Disseminated on Behalf of Citius Pharmaceuticals, Inc. Please see disclosures below. |
| Keep an Eye on Citius Pharmaceuticals |
| | | Hey Folks,
In hospitals and treatment centers across the country, certain critical care challenges persist — from catheter infections that cost billions annually to chronic conditions with no FDA-approved prescription treatments.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a late-stage biopharmaceutical company working to address several of these gaps, with three distinct product candidates spanning oncology, anti-infectives, and prescription therapeutics. |  | LYMPHIR: An FDA-Approved Cancer Immunotherapy Already Generating Revenue
Citius spun off its lead oncology asset, LYMPHIR, into a subsidiary called Citius Oncology. That subsidiary merged with a SPAC in August 2024, and just days before the merger closed, LYMPHIR received FDA approval for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL).
CTCL is a rare form of non-Hodgkin lymphoma that affects roughly 3,000 new patients each year, with an overall market estimated at $400 million. The condition is considered incurable, and patients face severe quality-of-life impacts including pain, itching, and disfiguring skin lesions. Systemic treatment options remain limited — which is exactly why LYMPHIR matters.
Here's where it gets interesting for investors:
- Citius Oncology officially launched LYMPHIR in December 2025 and reported $3.9 million in revenue during the fiscal first quarter ended December 31, 2025
- That revenue came from the very first weeks of commercialization through a nationwide network of specialty distributors
- The company deployed an AI-enabled commercial platform to support targeted physician engagement and optimize sales outreach
- Patients have already begun receiving LYMPHIR at leading cancer centers across the United States
Beyond the current approved indication, there is potential upside from investigator-initiated studies evaluating LYMPHIR in combination with pembrolizumab (the blockbuster checkpoint inhibitor behind Keytruda) for recurrent solid tumors, and as part of lymphodepletion regimens prior to CAR-T therapy. The company has also negotiated agreements to enable international patient access through Named Patient Programs in Europe and the Middle East. | | | Mino-Lok: Targeting a $2 Billion Global Problem
For patients who cannot avoid central venous catheters (CVCs) — thin tubes inserted into large veins in the chest, neck, or groin — infections are a constant threat. Every year, 7 million CVCs are used in the U.S., and 4 million of those are long-term, meaning they stay in place longer than a month. Each year, approximately 250,000 to 500,000 of these catheters become infected, resulting in conditions known as CLABSI and CRBSI.
The current standard of care is painful and costly:
- The infected catheter must be physically removed and replaced — a procedure that is extremely painful and can be traumatizing for vulnerable patients
- One study found that 57%–67% of patients experienced adverse physical and psychological symptoms from CVC removal and replacement
- 32% of those patients experienced moderate-to-severe symptoms
- The procedure alone costs approximately $10,000, and the overall treatment can run as high as $65,000
Many of these patients are already in fragile condition — undergoing chemotherapy, in the ICU, or receiving long-term nutrition.
Citius is developing Mino-Lok as the first and only FDA-approved antibiotic lock solution designed to actually salvage infected catheters rather than remove them. The product completed a full Phase 3 trial and reported topline results in May 2024, achieving the primary endpoint and several secondary endpoints with very high statistical significance.
Key developments for Mino-Lok include:
- Citius held a Type C meeting with the FDA in November 2024 that provided "clear, constructive, and actionable guidance" on the pathway to approval
- The company estimates the potential market at more than $1 billion in the U.S. and $2 billion globally
- Mino-Lok holds Qualified Infectious Disease Product (QIDP) designation, making it eligible for priority review and a rolling NDA submission
- The company is actively engaged with the FDA to outline next steps toward approval
If approved, Mino-Lok would address a genuine unmet need in hospital settings where catheter infections remain a persistent problem. | Halo-Lido: First Prescription Product Under Development for Hemorrhoids
Citius's third shot on goal is Halo-Lido, a proprietary topical formulation intended to provide anti-inflammatory and anesthetic relief for hemorrhoids.
Here's the overlooked detail: there is currently no FDA-approved prescription product to treat hemorrhoids. The condition affects roughly half of all adults over age 50, and the entire market is served exclusively by over-the-counter products. If Halo-Lido makes it through, it would be the first of its kind.
What the clinical data shows so far:
- Halo-Lido completed a very positive Phase 2b trial
- Citius is planning an End of Phase II meeting with the FDA to discuss next steps in the regulatory and clinical development program
- The company is actively engaged with the FDA regarding the path forward
- If approved, it would enter a massive untapped OTC-to-Rx market with no prescription competition
| | | When Founders Put Their Own Money on the Line
One of the strongest signals of conviction at any company is insider investment. At Citius, the numbers are hard to ignore.
- Co-founder and CEO Leonard Mazur has invested $22.5 million of his own money directly into the company
- Co-founder and Executive Vice Chairman Myron Holubiak has invested $4 million
- That's $26.5 million in combined insider investment
- The leadership team brings deep pharmaceutical experience, including Mazur's veteran executive background, Holubiak's history as president of a major pharma company, and Chief Medical Officer Dr. Myron Czuczman's extensive oncology expertise from his time at Regeneron
| | | Why the Timing Could Be Interesting
Citius Pharmaceuticals has multiple near-term catalysts that could each independently move the needle. LYMPHIR revenue is expected to ramp as physician adoption increases. Mino-Lok's FDA discussions are ongoing, with QIDP designation providing a potential fast track. And Halo-Lido could provide updates following the planned FDA meeting.
For those interested in late-stage biotech companies with FDA-approved products, CTXR presents an interesting combination of assets worth monitoring.
Anyways...
That's all for now!
Until Next Time, -ZT Team | P.S. Want our text alerts? Text "ZIPTRADER" to 1-(855)-228-1598 to sign up!
(standard carrier data/text rates apply) |
|
|
|---|
|
*Disseminated on Behalf of Citius Pharmaceuticals, Inc. Please see disclosures below. |
|
|---|
|
| | 5101 SANTA MONICA BLVD STE 8 #62, 90029, LOS ANGELES, CA |
| This email was sent to diansastroxz.forex@blogger.com |
| *SPONSORED CONTENT* ZipTrader LLC is a publishing company, we are not financial advisors. This is not financial advice. Investments involve risk and are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance. ZipTrader has been compensated thirty-four thousand USD by ACH Bank Transfer by TD Media LLC to distribute media via YouTube, email, and SMS on behalf of Citius Pharmaceuticals, Inc. (CTXR) from March 10, 2026 to March 11, 2026. ZipTrader has been compensated nineteen thousand five hundred USD by ACH Bank Transfer by Lifewater Media to distribute media via email and SMS for Citius Pharmaceuticals Inc. (CTXR) on November 11, 2024. ZipTrader has been compensated seventeen thousand five hundred USD by ACH Bank Transfer by Lifewater Media to distribute media via email and SMS for Citius Pharmaceuticals Inc. (CTXR) from August 4, 2024 to August 5, 2024. ZipTrader has been compensated twenty thousand USD by ACH Bank Transfer by Lifewater Media to distribute media for Citius Pharmaceuticals Inc. (CTXR) on January 25, 2023. ZipTrader has been compensated fifteen thousand USD by ACH Bank Transfer by Lifewater Media to distribute media via email and SMS for Citius Oncology Inc. (CTOR) on September 23, 2024. Citius Oncology Inc. (CTOR) is a subsidiary of Citius Pharmaceuticals Inc. (CTXR). ZipTrader may receive additional campaigns in the future by TD Media LLC to distribute media for Citius Pharmaceuticals, Inc. (CTXR). As a result of this advertisement and other marketing efforts, ZipTrader may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of ZipTrader do not hold a position in Citius Pharmaceuticals, Inc. (CTXR). This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Citius Pharmaceuticals, Inc. (CTXR), increased trading volume, and possibly an increased share price of Citius Pharmaceuticals, Inc. (CTXR), which may or may not be temporary and decrease once the marketing arrangement has ended. |
| BY READING THIS EMAIL & ALL ZIPTRADER CONTENT YOU AGREE: This is not financial advice. You must do your own due diligence on all information. ZIPTRADER LLC is a publishing company and we provide general information, opinions, & news coverage to viewers. However – we do not provide personalized financial advice, are not financial advisors, and our opinions are not suitable for all investors. You should not treat any opinion as expressed as a specific inducement to make a particular investment or follow a particular strategy, but just as an opinion. Use at your own risk. Past Performance is not indicative of future results, and any results presented are not typical, and should not be understood as typical. Actual results vary given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. TRADING IS RISKY: Most traders in all markets lose all of their money (and more if they use margin). Most small businesses fail. Do NOT partake in trading, investing, entrepreneurship or any other risky endeavor covered here if you are not prepared with the reality that most fail. We reserve the right to have affiliate relationships with advertisers/sponsors. See Full Terms of Service. See Our Advertisement Disclaimer. |
| | |
|
|
|---|
|
|
|
Post a Comment
Post a Comment